Jin Ji

Dr. Jin Ji

Changhai hospital

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
YLYun Li
Yun Li
JJJin Ji
Jin Ji
JLJi Lyu
Ji Lyu
XJXin Jin
Xin Jin
XHxing he
xing he
FWFubo Wang
Fubo Wang
Purpose: This study aimed at developing and validating a novel noninvasive urinary exosome-based post-DRE (digital rectal examination) lncRNA assay to diagnose PCa (prostate cancer) and clinically significant PCa (Gleason score ≥ 7) from the initial prostate biopsy. Methods: A total of 602 urine samples from eligible participants were collected. The expression levels of urinary exosomal PCA3 (prostate cancer antigen 3) and MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) were detected by qPCR (quantitative real-time PCR). Receiver operating characteristic (ROC) analysis was applied to evaluate the diagnostic performance of PCA3, MALAT1 and the lncRNA assay. A decision curve analysis (DCA) and waterfall plots were used to assess the clinical value of the lncRNA assay. Results: Urinary exosomal PCA3 and MALAT1 were overexpressed in PCa and clinically significant PCa (p < 0.001). The lncRNA assay combining PCA3 and MALAT1 had a better diagnostic performance (AUC 0.828) than the current clinical parameters in detecting PCa. More importantly, the lncRNA assay yielded an AUC of 0.831 to detect clinically significant PCa, which is much higher than that of the current clinical parameters. The lncRNA assay was superior to PSA, f/tPSA and the base model for detecting PCa and clinically significant PCa, with a higher net benefit for almost all threshold probabilities. At the cutoff value of 95% sensitivity, the lncRNA assay could avoid 24.2% unnecessary biopsies while only missing 1.2% of the cases of clinically significant PCa. Conclusion: We developed and validated a novel noninvasive post-DRE urine-based lncRNA assay that presented good diagnostic power and clinical utility for the early diagnosis of PCa and high-grade PCa.

10 April 2019 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
JJJin Ji
Jin Ji
HZHan Zhang
Han Zhang
DXDa Xu
Da Xu
TZTianyi Zhang
Tianyi Zhang
DKDepei Kong
Depei Kong
YSYing-Hao Sun
Ying-Hao Sun

1 July 2025 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
XSXianqi Shen
Xianqi Shen
ZLZijian Li
Zijian Li
YSYuchuan Shi
Yuchuan Shi
ZZZenghui Zhou
Zenghui Zhou
YWYan Wang
Yan Wang
XGXu Gao
Xu Gao
Background: Poly(A) binding protein cytoplasmic 4 (PABPC4) has been regarded as a prognostic marker in many malignancies. In this study, we evaluated PABPC4 expression at both messenger ribonucleic acid (mRNA) and protein levels. The prognostic value of PABPC4 in patients with prostate cancer (PCa) was also investigated. Methods: The Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) database, our analysis of Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA), and 65 pairs of ribonucleic acid (RNA) sequencing data from our center were employed to detect the expression of PABPC4 in PCa tissues. Tissue microarrays (TMAs) were utilized to detect the expression of the PABPC4 protein, and survival analysis as well as risk factor analysis were conducted. Results: In the 65 pairs of sequencing data, the expression of PABPC4 in tumor tissues was significantly higher than that in paired adjacent tissues (P<0.001), and its expression also presented significant differences among different Gleason groups (P=0.041). In the CPGEA data, the expression of PABPC4 in tumor tissues was significantly higher than that in control tissues (P<0.001), and the expression of PABPC4 in M1 patients was higher than that in M0 patients, although no significant statistical difference was shown (P=0.051). In the TCGA data, the expression of PABPC4 in tumor tissues was significantly higher than that in control tissues (P<0.001). The expression of pT3/4 (pathological tumor stage 3 and pathological tumor stage 4) in high-stage tumor tissues was significantly higher than that in low-stage tumor tissues (pT2) (P=0.02), the expression of pT3/4 in GSE21034 and GSE32571 tumor tissues was significantly higher than that in control tissues (P<0.001), and the expression of pT3/4 in primary tumor tissues was higher than that in metastatic tissues in GSE6752 (P<0.001). The TCGA data revealed that patients with high PABPC4 expression had poorer overall survival (OS) than those with low PABPC4 expression (P=0.04), and the TMA data indicated that patients with high PABPC4 expression had a poor prognosis (P=0.004). Conclusions: Our study demonstrated that PABPC4 was overexpressed at mRNA and protein levels in PCa. We found that patients with high PABPC4 expression had a shorter biochemical recurrence (BCR)-free survival and OS, showing its value as a prognostic biomarker in patients with PCa.

30 June 2022 in Journal of Chromatography B
Verified
Journal Article
Open access
CYChungen Yao
Chungen Yao
XCXi Chen
Xi Chen
YXYalong Xu
Yalong Xu
FWfubo wang
fubo wang
JJJin Ji
Jin Ji
YLYun Li
Yun Li
Extracellular vesicles (EVs) are membranous vesicles released by various cells, and are involved in intercellular communication and disease progression. EVs that are isolated from urine are good indicators of urinary system diseases and help certain urological studies. During isolation of urine EVs, Dithiothreitol (DTT) is widely used to reduce the contamination of the major contaminant Tamm-Horsefall protein (THP),which is the most abundant protein in the human urine and the most difficult contaminant to remove in the isolation of urine EVs. Unfortunately, DTT can interfere with subsequent analysis due to its strong reducing ability and cannot completely remove THP. To optimize the urine EV isolation strategy, we compared two pretreatment protocols: incubating urine with NaCl and DTT before centrifugation. After a series of analyses by nanoparticle tracking analysis (NTA), western blotting (WB), and transmission electron microscopy (TEM), we found that NaCl removed more THP than DTT in a low-speed centrifugation step and that the residual EVs also had lower THP contamination post NaCl treatment. Remarkably, the yield of EVs obtained via the salting-out method was significantly higher than those obtained by the other methods (P = 0.001). Our study is the first to demonstrate that the salting-out method is better than the traditional DTT method in terms of efficiency in removing THP and EV yields.

19 January 2026 in Saudi Journal of Medicine & Medical Sciences
Verified
Journal Article
Open access
YDYang Ding
Yang Ding
MFMin Fang
Min Fang
JJJin Ji
Jin Ji
GNGang Nie
Gang Nie
Splenic rupture constitutes a rare yet potentially life-threatening complication following colonoscopy. We report a case of a young male patient who presented with abdominal pain for 2 days, which began 6 hours after colonoscopy. Clinical examination revealed periumbilical tenderness, with laboratory findings significant for leukocytosis (WBC: 20.32 × 10 9 /L), an initial hemoglobin of 113 g/L, and a significantly elevated D-dimer (15.25 mg/L). Abdominal computed tomography confirmed splenic rupture, perisplenic hematoma, and hemoperitoneum. Following multidisciplinary consultation involving hepatobiliary surgery and interventional radiology, the patient underwent emergent splenic artery embolization. Post-procedural management included antibiotics and supportive care. Despite achieving hemodynamic stability and symptomatic improvement, persistent leukocytosis and a significant hemoglobin decrease to 79 g/L were noted on postoperative day 1, accompanied by radiographic evidence of increased hemoperitoneum. Nonetheless, the patient remained hemodynamically stable and received ongoing supportive care, and was discharged in good condition after a hospital stay of 15 days. This case highlights the importance of maintaining a high index of suspicion for splenic injury in patients with post-colonoscopy abdominal pain, even with delayed presentation, and demonstrates the use of splenic artery embolization as a therapeutic intervention, and the need for prolonged monitoring.